Bonus Biogroup Valuation
| BONS Stock | ILS 10.80 0.10 0.93% |
At this time, the firm appears to be overvalued. Bonus Biogroup shows a prevailing Real Value of S10.32 per share. The current price of the firm is S10.8. Our model approximates the value of Bonus Biogroup from analyzing the firm fundamentals such as Return On Equity of -0.55, current valuation of 169.66 M, and Shares Owned By Insiders of 49.72 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bonus Biogroup's price fluctuation is not too volatile at this time. Calculation of the real value of Bonus Biogroup is based on 3 months time horizon. Increasing Bonus Biogroup's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bonus Biogroup is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bonus Stock. However, Bonus Biogroup's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.8 | Real 10.32 | Hype 10.8 | Naive 10.78 |
The real value of Bonus Stock, also known as its intrinsic value, is the underlying worth of Bonus Biogroup Company, which is reflected in its stock price. It is based on Bonus Biogroup's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bonus Biogroup's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bonus Biogroup helps investors to forecast how Bonus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bonus Biogroup more accurately as focusing exclusively on Bonus Biogroup's fundamentals will not take into account other important factors: Bonus Biogroup Total Value Analysis
Bonus Biogroup is currently forecasted to have takeover price of 169.66 M with market capitalization of 223.15 M, debt of 6.28 M, and cash on hands of 3.6 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bonus Biogroup fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
169.66 M | 223.15 M | 6.28 M | 3.6 M |
Bonus Biogroup Asset Utilization
One of the ways to look at asset utilization of Bonus is to check how much profit was generated for every dollar of assets it reports. Bonus Biogroup shows a negative utilization of assets of -0.0636 percent, losing S6.36E-4 for each shekel of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each shekel of assets it shows. Put another way, asset utilization of Bonus Biogroup shows how discouraging it operates for each shekel spent on its assets.Bonus Biogroup Ownership Allocation
Bonus Biogroup holds a total of 1.17 Billion outstanding shares. Bonus Biogroup retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bonus Biogroup Profitability Analysis
Net Loss for the year was (90.08 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bonus Biogroup's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bonus Biogroup and how it compares across the competition.
About Bonus Biogroup Valuation
The stock valuation mechanism determines Bonus Biogroup's current worth on a weekly basis. Our valuation model uses a comparative analysis of Bonus Biogroup. We calculate exposure to Bonus Biogroup's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bonus Biogroup's related companies.Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd., formerly known as Oceana Advanced Industries Ltd., was founded in 1981 and is based in Haifa, Israel. BONUS BIOGROUP is traded on Tel Aviv Stock Exchange in Israel.
8 Steps to conduct Bonus Biogroup's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bonus Biogroup's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bonus Biogroup's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bonus Biogroup's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bonus Biogroup's revenue streams: Identify Bonus Biogroup's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bonus Biogroup's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bonus Biogroup's growth potential: Evaluate Bonus Biogroup's management, business model, and growth potential.
- Determine Bonus Biogroup's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bonus Biogroup's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Bonus Stock analysis
When running Bonus Biogroup's price analysis, check to measure Bonus Biogroup's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bonus Biogroup is operating at the current time. Most of Bonus Biogroup's value examination focuses on studying past and present price action to predict the probability of Bonus Biogroup's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bonus Biogroup's price. Additionally, you may evaluate how the addition of Bonus Biogroup to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |